登记标题,引自 ClinicalTrials.gov(英文原文,暂无中文译文)
Culmerciclib Plus Anlotinib and Endocrine Therapy for HR-Positive/HER2-Negative Metastatic Breast Cancer With Brain Metastases
ClinicalTrials.gov 上登记的一项乳腺癌开放试验,由中山大学肿瘤防治中心牵头,本站收录的另外 8 家医院列为研究中心。
状态、分期和开始时间依据 ClinicalTrials.gov 在 2026年11月18日 的登记,登记库此后可能已有更新。能否参加由研究团队决定。不构成医疗建议。
研究团队的联系方式见登记记录。本站不转递咨询。
列出这项试验的中国大陆医院 9
登记记录中列为牵头方或研究中心、且为本站收录的医院(研究中心为开放状态)。牵头方在前,研究中心按英文名称字母排序。
- 牵头方(推断)中山大学肿瘤防治中心Sun Yat-sen University Cancer Center广州医院页面
- 研究中心安阳市肿瘤医院Anyang Tumor Hospital安阳医院页面
- 研究中心河北医科大学第四医院Fourth Hospital of Hebei Medical University石家庄医院页面
- 研究中心河南省肿瘤医院Henan Cancer Hospital郑州医院页面
- 研究中心Nanchang People's Hospital南昌医院页面
- 研究中心南京鼓楼医院Nanjing Drum Tower Hospital南京医院页面
- 研究中心大连医科大学附属第二医院Second Hospital of Dalian Medical University大连医院页面
- 研究中心四川省人民医院Sichuan Provincial People's Hospital成都医院页面
- 研究中心浙江省肿瘤医院Zhejiang Cancer Hospital杭州医院页面
登记记录可能还列有其他研究中心(包括中国大陆以外),各中心在试验期间也可能开放或关闭。在 ClinicalTrials.gov 查看全部研究中心
来源:ClinicalTrials.gov 登记记录 NCT07745257,读取于 2026年11月18日;医院名称与本站医院名单匹配。 名称如何匹配
这项试验的核对清单 5
只列这项试验的登记记录有明确答案的要点:登记的年龄和性别,以及写明数值、评分、分期或具体检查的标准条目。与医疗资料对照后可勾选。条目为英文原文,暂无中文译文。
展开清单(5 项)收起清单
18 岁 至 80 岁;性别:仅女性
登记记录的入选字段
histologically or cytologically documented HR+/HER2- breast cancer
入选标准第 4 条
No more than 3 lines of prior systemic therapy for advanced disease
入选标准第 9 条
No more than 1 line of chemotherapy or antibody-drug conjugate (ADC) administered in the advanced setting
入选标准第 10 条
No prior CDK4/6 inhibitor therapy for advanced disease, or only 1 line of CDK4/6 inhibitor therapy with treatment duration > 6 months
入选标准第 11 条
Women of child bearing potential must agree to use a contraceptive method during the treatment period and for at least 180 days after the last dose of experiment treatment
入选标准第 13 条
Unresolved Grade ≥2 toxicities (per CTCAE Version 6.0) attributable to any prior therapy, except alopecia
排除标准第 3 条
ECOG PS of 0-1
入选标准第 2 条
Other malignancies diagnosed within 5 years, excluding cured non-melanoma skin cancer, cervical carcinoma in situ and papillary thyroid carcinoma
排除标准第 7 条
勾选只留在本页面,不保存、不发送。各项都符合也不等于能够参加,由研究团队经筛查后决定。需要研究团队判断的条目(如 “sufficient organ function”)不在此清单中,见下方完整标准。 本记录没有明确写出:分期或严重程度(按试验的定义);化验:血常规、肝肾功能;影像与可测量病灶;怀孕、哺乳与避孕。
按固定关键词规则从登记记录中选出(非 AI,未经人工核对),引自 ClinicalTrials.gov, NCT07745257,读取于 2026年11月10日。
登记的入选标准
依据 ClinicalTrials.gov 的登记,读取于 2026年11月10日,未删减。以下为英文原文,暂无中文译文。符合书面条件并不等于能够参加,由研究团队经筛查后决定。
入选标准:Inclusion Criteria:
Women aged ≥ 18 years ECOG PS of 0-1 Life expectancy of at least 12 weeks histologically or cytologically documented HR+/HER2- breast cancer radiologically confirmed brain parenchymal metastases without the need for immediate local therapy measurable brain metastasis lesion according to RANO-BM criteria Must have active brain metastases, defined as newly diagnosed brain metastases or progressive brain metastases following prior local therapy Prior systemic therapy must meet all the following criteria: No more than 3 lines of prior systemic therapy for advanced disease No more than 1 line of chemotherapy or antibody-drug conjugate (ADC) administered in the advanced setting No prior CDK4/6 inhibitor therapy for advanced disease, or only 1 line of CDK4/6 inhibitor therapy with treatment duration > 6 months Adequate hematological, hepatic and renal function Women of child bearing potential must agree to use a contraceptive method during the treatment period and for at least 180 days after the last dose of experiment treatment Patients must be able to participate and comply with treatment and follow-up排除标准:Exclusion Criteria:
Patients with leptomeningeal metastases, brainstem metastases or skull metastases Prior receipt of anti-angiogenic agents or Culmerciclib Unresolved Grade ≥2 toxicities (per CTCAE Version 6.0) attributable to any prior therapy, except alopecia Patients with visceral crisis,defined as severe organ dysfunction assessed by symptoms, signs, laboratory examinations and rapid disease progression Inability to swallow capsules or tablets Any severe and/or uncontrolled medical disease Other malignancies diagnosed within 5 years, excluding cured non-melanoma skin cancer, cervical carcinoma in situ and papillary thyroid carcinoma Radiographic evidence of tumor invasion of major vessels, or high risk of tumor invasion into major vessels resulting in life-threatening hemorrhage as assessed by the investigator Patients with arterial or venous thromboembolic events within 6 months, such as cerebrovascular accident, deep vein thrombosis and pulmonary embolism Participation in other anti-tumor clinical trials within 4 weeks prior to enrollment Any other condition that the investigator considers inappropriate to participate in this trial
引自 ClinicalTrials.gov, NCT07745257, 参与标准,读取于 2026年11月10日。
这些信息从哪里来
登记记录
ClinicalTrials.gov(美国国家医学图书馆),登记记录 NCT07745257,读取于 2026年11月18日。总体状态为正在招募、即将招募或邀请入组、且至少有一家列出医院的研究中心开放的试验,在本站有单独页面。仅在中国临床试验注册中心(ChiCTR)登记的试验没有计入。
疾病与医院
本站在 ClinicalTrials.gov 按疾病检索中国的试验,检索到这项试验,就把它列在该病下。登记记录中的牵头方和研究中心名称与本站医院名单匹配(ROR 编号与核对过的别名)。 定义
没有收录的内容
登记记录中研究者和联系人的姓名,以及记录之外的任何信息。标题和入选标准引自登记记录。